Today: 20 May 2026
Browse Category

NASDAQ:HIMS 29 September 2025 - 11 May 2026

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health reports first-quarter results Monday after the market close, with Wall Street expecting about $617 million in revenue and EPS of 3 to 4 cents. Investors are watching whether its weight-loss business can grow after it stopped broadly marketing compounded GLP-1 drugs and shifted to FDA-approved options from Novo Nordisk. Hims shares closed at $28.46 Friday, rising to $29.07 after hours.
11 May 2026
····
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom

Hims & Hers Health shares rose 10.2% to $28.27 on Friday ahead of first-quarter results due Monday. Analysts expect Q1 revenue near $616.9 million and earnings of 3 cents per share. The company recently reached a deal with Novo Nordisk to offer Ozempic and Wegovy, and added Eli Lilly’s Zepbound and Foundayo to its platform. The FDA is considering tighter rules on compounding GLP-1 drugs.
9 May 2026
···
Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot

Hims & Hers Stock Rallies After JPMorgan Bets On Its GLP-1 Pivot

Hims & Hers shares jumped about 9% Friday after JPMorgan initiated coverage with an overweight rating and a $35 price target. The move comes as Hims announced access to Eli Lilly’s Zepbound and Foundayo through LillyDirect, though the company said it is not affiliated with Lilly. Hims shares recently traded at $30.70. The company serves about 2.5 million subscribers.
24 April 2026
·
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.
21 April 2026
·····
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Health shares jumped 8.9% Monday morning, extending a 48.3% weekly gain ahead of its May 11 earnings report. The FDA will meet in July to consider rules on compounding peptides, a market Hims entered last year. Hims ended 2025 with 2.511 million subscribers and $617.8 million in fourth-quarter revenue, up 28%. Omnicell reported $314 million in fourth-quarter revenue and a $2 million net loss.
20 April 2026
····
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares jumped 5.9% to $23.47 Tuesday after announcing a distribution deal with Novo Nordisk, extending a two-day gain to 49%. Novo withdrew its lawsuit against Hims as part of the pact, which will bring Ozempic and Wegovy to Hims’ platform and phase out most compounded GLP-1 drugs. Analysts raised price targets but warned branded drugs could lower margins. Regulatory risks remain.
11 March 2026
··
Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Health shares jumped premarket Monday after reports that Novo Nordisk will sell weight-loss drugs through its platform, with an announcement expected the same day. The move follows a recent patent dispute and comes as the FDA increases scrutiny of compounded GLP-1 drugs. Hims previously pulled a compounded Wegovy pill after FDA threats and a Novo lawsuit. The companies had partnered before but split last June over marketing concerns.
9 March 2026
···
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.
26 February 2026
···
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Hims & Hers will stop offering a compounded semaglutide pill after the FDA signaled a crackdown on copycat GLP-1 drugs. Hims shares fell 15.9% to $19.36 on Friday. Molina Healthcare plunged over 28% after forecasting 2026 profit far below expectations and announcing an exit from Medicare Advantage prescription drug plans. The Health Care Select Sector SPDR Fund closed up 1.85% at $157.71.
8 February 2026
··
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers shares fell 2.2% to $31.00 in premarket trading Monday after a 6.4% drop Friday. The decline followed Amazon Pharmacy’s move to offer Novo Nordisk’s Wegovy weight-loss pill nationwide, intensifying competition in the online obesity drug market. Investors are watching Hims’ upcoming earnings for signs of pressure on its GLP-1 business and marketing costs.
12 January 2026
·
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers Health shares dropped 6.4% to $31.69 Friday, extending a two-day slide to 11% after Amazon Pharmacy entered the Wegovy weight-loss pill market. BofA cut its price target and kept an Underperform rating, citing high 2026 estimates. The stock closed below key moving averages and neared oversold levels. The FDA previously warned the company over marketing claims for compounded weight-loss drugs.
10 January 2026
··
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers shares dropped 5.3% to $32.06 after Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill. Bank of America cut its price target on Hims, citing margin and spending risks for 2026. The stock fell from an intraday high of $34.35. Investors are watching for signs of pricing pressure and updated forecasts ahead of Hims’ next earnings report.
9 January 2026
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS shares are up about 110% year-to-date, trading near $58 in late September 2025 after peaking at $73 in February and weathering sharp drops on weak Q2 results and FDA warnings. Q2 revenue rose 73% to $544.8 million, missing estimates, with net income at $42.5 million. HIMS expanded into GLP-1 weight-loss drugs and new prescription categories, and agreed to acquire UK-based Zava for European growth.
29 September 2025
·

Stock Market Today

No summaries found on the roundup post.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Go toTop